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ment of cancer. A better understanding of how resistance arises and what molecular alter-
ations correlate with resistance is the key to developing novel effective therapeutic
strategies. To investigate the underlying mechanisms of gemcitabine (Gem) resistance and pro-
vide possible therapeutic options, three Gem-resistant urothelial carcinoma sublines were es-
tablished (NG0.6, NG0.8, and NG1.0). These cells were cross-resistant to arabinofuranosyl
cytidine and cisplatin, but sensitive to 5-fluorouracil. The resistant cells expressed lower
values of [hENT1  dCK/RRM1  RRM2] mRNA ratio. Two adenosine triphosphate-binding
cassette proteins ABCD1 as well as multidrug resistance protein 1 were elevated. Moreover, cy-
clin D1, cyclin-dependent kinases 2 and 4 were upregulated, whereas extracellular signal-
regulated kinase 1/2 and p38 mitogen-activated protein kinase (MAPK) activity were repressed
significantly. Administration of p38 MAPK inhibitor significantly reduced the Gem sensitivity in
NTUB1 cells, whereas that of an extracellular signal-regulated kinase MAPK inhibitor did not.
Furthermore, the Gem-resistant sublines also exhibited higher migration ability. Forced
expression of p38 MAPK impaired the cell migration activity and augmented Gem sensitivityave no conflicts of interest to declare.
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324 Y.-T. Kao et al.in NG1.0 cells. Taken together, these results demonstrate that complex mechanisms were
merged in acquiring Gem resistance and provide information that can be important for devel-
oping therapeutic targets for treating Gem-resistant tumors.
Copyright ª 2014, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Urinary bladder cancer is the second most common malig-
nancy of the genitourinary tract [1]. Urothelial carcinoma
(UC) is the most common subtype and accounts for more
than 90% of all bladder cancers [2,3]. UC ranks 14th among
the causes of cancer deaths; its incidence and mortality
rate are increasing gradually in Taiwan. The treatment for
UC is mainly surgery, followed by chemotherapy or radio-
therapy [4].
Prediction of clinical outcomes and responses to
chemotherapy are improving, but the mechanism is still not
fully understood [5]. Resistance to chemotherapy is a major
obstacle in cancer treatment, and the underlying molecular
mechanisms remain unclear. Gemcitabine (20-deoxy-20,20-
difluorocytidine; Gem) plus cisplatin regimen has been used
widely, but with less improvement in advanced and meta-
static bladder tumors [6e8]. Gem is an antimetabolic agent
and has widely been employed to treat various cancers,
including non-small-cell lung cancer, pancreatic cancer,
breast cancer, and bladder cancer. Gem enters cells pre-
dominantly through human equilibrative nucleoside
transporter-1 (hENT1) [9]. When activated by deoxycytidine
kinase (dCK), Gem interferes with DNA replication and in-
hibits tumor cell growth through the inhibition of ribonu-
cleotide reductase subunits M1 and M2 (RRM1 and RRM2)
[10]. Nakano et al. [11] reported that the ratio of
[hENT1  dCK/RRM1  RRM2] gene expression is inversely
correlated to the acquired Gem resistance, and can serve
as a predictive marker for Gem resistance.
Impaired drug delivery and increased drug metabolism
are two main mechanisms accounting for the development
of drug resistance in tumors [12]. Adenosine triphosphate-
binding cassette (ABC) transporters belong to membrane-
bound protein superfamilies that transport exogenous and
endogenous substances across membranes [13e15]. Multi-
drug resistance proteins (MRPs⁄ABCCs) are the most com-
mon ABC transporters of cytotoxic drugs. The MRP family
comprises nine transporters. Several reports showed
controversial results for ABC proteins in Gem-induced
cytotoxicity and acquired resistance [9,16e20]. Thus, a
more detailed analysis is needed.
The mitogen-activated protein kinase (MAPK) pathway is
oneof themost important signaling pathways that respond to
various cellular stimuli [21,22]. Extracellular signal-
regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and
p38 MAPK pathways are known molecular targets for drug
development [23]. The p38 MAPK activation has been sug-
gested to be involved in Gem-induced apoptosis in pancre-
atic cancer [24]. Gem induces apoptosis by blocking the G1/S
phase progression [25]. It has been shown that an increased
p27kip1 level was associated with Gem resistance [26].We have established three Gem-resistant UC sublines
[26]. In this study, we further characterized these Gem-
resistant sublines to identify the molecular features that
are associated with Gem-resistant phenotypes. In summary,
we provide evidence suggesting that multiple mechanisms
were merged to evoke acquired Gem resistance in UC. This
study provides important information for developing a
targeted gene therapy to reverse Gem resistance in UC
cancer.
Materials and methods
Reagents and antibodies
All reagents were purchased from Sigma Chemical Co. (St
Louis, MO, USA) unless indicated specifically. Gem was ac-
quired from Eli Lilly France (Fegersheim, France). Cisplatin
was acquired from Pharmacia & Upjohn (Milan, Italy). An-
tibodies against specific proteins (MRP1, ABCD1, p21, cyclin
D1, and MRP9) were purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA); multidrug resistance protein
1 (MDR1), p27Kip1, and a-tubulin from Genetex Inc. (Irvine,
CA, USA); phospho-ERK, phospho-p38, and p38 from Cell
Signaling Technology (Beverly, MA, USA); and goat anti-
mouse IgGeHRP and goat antirabbit IgGeHRP from Jackson
Laboratory (Bar Harbor, ME, USA).
Cell culture and establishment of Gem-resistant
sublines
NTUB1, a human UC cell line, was established from a high-
grade bladder cancer [27] and maintained as described
previously [28]. Three sublines that could survive at Gem
concentrations of 0.6 mM, 0.8 mM, and 1.0 mM were estab-
lished and designated as NG0.6, NG0.8, and NG1.0,
respectively [26].
Cytotoxicity analysis by MTT assay
Cellular cytotoxicity to drugs was performed using a
modified 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetraz-
olium bromide (MTT) assay according to a method
described previously [28]. Proportions of surviving cells
were determined by absorbance at 540 nm using a micro-
plate reader, MRX (Dynex Technologies, Chantilly, VA, USA).
Cell viability was expressed relative to the untreated con-
trol. The IC50 values of each group were calculated by the
median-effect analysis and presented as mean  standard
deviation. The relative resistance (RR) ratio of Gem-
resistant sublines to tested drugs was determined as the
ratio of IC50 values to parental NTUB1 cells.
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transcription polymerase chain reaction
Total RNA was isolated and cDNAs were reverse-
transcribed, as described previously [28]. Quantitative
real-time polymerase chain reaction was performed with
specific primers listed in Table 1, according to a previously
described method [26]. Cyclophilin A gene served as the
normalization control. The relative abundance of mRNAs
was expressed as fold changes. All samples were analyzed
independently at least twice for each gene.Western blotting analysis
Cells were harvested and subjected to sodium dodecyl
sulfate polyacrylamide gel electrophoresis and Western
blotting analysis with indicated antibodies, as described
previously [26]. Signals were detected by a chemilumines-
cent enhanced chemiluminescence (ECL) reagent and
visualized on a Fuji SuperRX film.Flow cytometry analysis
Cellular DNA content was determined following propidium
iodide staining, as described previously [28]. Production of
intracellular reactive oxygen species was analyzed with
2070-dichlorofluorescein diacetate (Sigma Chemical Co.)
using a FACScan flow cytometer (Becton Dickinson, Franklin
Lakes, NJ, USA) [28].Clonogenic assays
Five hundred cells of NTUB1 and Gem-resistant sublines
were seeded, treated with indicated dosages of Gem for 2
hours, washed with phosphate-buffered saline, and trans-
ferred to a fresh drug-free medium. Giemsa staining was
then employed to measure the extent of cell growth after 7
days. Clonogenic efficiency for each condition was deter-
mined in relation to numbers obtained for untreated con-
trol cells.Table 1 Primers used in this study.
Gene Primer sequence (50–>30)
hENT1 F: AAAGGAGAGGAGCCAAGAGC
R: GGCCCAACCAGTCAAAGATA
hdCK F: CCCGCATCAAGAAAATCTCC
R: TCATCCAGTCATGCCAGTC
hRPM1 F: GGAGGAATTGGTGTTGCTGT
R: GCTGCTCTTCCTTTCCTGTG
hRPM2 F: CCCGCTGTTTCTATGGCTTC
R: CCCAGTCTGCCTTCTTCTTG
Cyclophilin A F: GTCAACCCCACCGTGTTCTT
R: CTGCTGTCTTTGGGACCTTGT
F Z forward sequence; hdCK Z human deoxycytidine kinase;
hENT-1 Z human equilibrative nucleoside transporter-1;
R Z reverse sequence.Wound healing migration assay
Cells were seeded onto a 24-well plate containing an IBIDI
culture insert (IBIDI GmbH, Martinsried, Germany) and
incubated at 37C with 5% CO2, according to the manufac-
turer’s instruction. After an overnight culture, the insert
was removed to create a gap ofw500 mm. The migration of
cells was observed and recorded 16e24 hours post insert
removal using an inverted Olympus CKX41 microscope
equipped with an Olympus C-7070 digital camera (Olympus,
Tokyo, Japan) at 200  magnification. The width of the
wound space was measured and calculated by the program
Image J (http://rsb.info.nih.gov/ij/). Wound closure was
determined as the difference between wound width at
0 hour and that at 16 hours or 24 hours, and expressed as a
ratio to the 0-hour value.
Statistical analysis
All data were presented as mean  standard error and
compared using the Student t test.
Results
Establishment and characterization of Gem-
resistant sublines
To explore the molecular mechanism of Gem resistance in
cancer patients, NG0.6, NG0.8, and NG1.0 sublines were
established by continuous exposure to increasing doses of
Gem and were stably maintained for more than 20 passages
[26]. The sublines showed no apparent morphologic
changes (Fig. 1A) but exhibited a slower growth rate than
the parental cells (Fig. 1B). NG sublines showed more sub-
G1, fewer G1 cells, and slightly increased S-phase pop-
ulations in the absence of Gem (Fig. 1C). Furthermore,
these sublines displayed significant survival as compared
with NTUB1 cells in the clonogenic assay (Fig. 1D).
Altered drug sensitivity of Gem-resistant sublines
The cytotoxicity of NG sublines was examined in response
to arabinofuranosyl cytidine (Ara-C), 5-fluorouracil (5-FU),
and cisplatin using an MTT assay. The IC50 values and RR
ratios are listed in Table 2. The RR ratios of the sublines to
Gem were 1342e1900-fold, as described previously [26].
The Gem-resistant sublines showed significant Ara-C resis-
tance (RR ratio, 1244.79e2893.27-fold) but mild sensitivity
to 5-FU (RR ratio, 0.54e0.68-fold). In addition, NG cells also
showed significant resistance to cisplatin (RR ratio,
1.2e1.42-fold), which is commonly used for UC treatment.
Gem-resistant cells have increased migratory
potential, reduced reactive oxygen species levels,
and altered Gem metabolism gene expression
Metastasis of tumors affects severely the morbidity and
mortality of cancer patients [29]. A wound healing assay
was performed to examine the metastatic properties of NG
sublines. NG sublines showed greater migratory activity and
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Figure 1. Growth and Gem response of NTUB1 and Gem-resistant sublines. (A) NTUB1, NG0.6, NG0.8, and NG1.0 cells were
cultured and photographed (20). (B) Indicated cells were seeded in 96-well plates and analyzed by an MTT assay for 3 consecutive
days. Data were expressed as the ratio of cell numbers from Day 2 or Day 3 to Day 1. Five wells were analyzed in two separate
experiments. (C) Indicated cells were harvested at the subconfluent stage and analyzed by flow cytometry. Data were from six
independent experiments. (D) Cells were seeded and treated with indicated doses of Gem for 2 hours. After PBS washing, the cells
were incubated with a fresh medium and cultured for another 7 days. Colonies were stained with Giemsa and counted. * p < 0.05.
**p < .01. ***p < 0.005, compared to NTUB1 at the same dose. ###p < 0.005, compared to NTUB1 CT. Gem Z gemcitabine;
MTT Z modified 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide; PBS Z phosphate buffered saline.
326 Y.-T. Kao et al.correlated with the resistance (Fig. 2A and B). Combining
this result with the fact that NG sublines exhibited slower
growth properties (Fig. 1B), one could conclude that NG
sublines indeed gained a marginal advantage. In addition,
the level of cellular reactive oxygen species was reduced
gradually in NG cells (Fig. 2C).
Quantitative real-time polymerase chain reaction was
performed to analyze the expression of four nucleoside
metabolism genes in NG sublines. The ratio of four nucle-
oside metabolism gene expressions [hENT1  dCK/
RRM1  RRM2] decreased dramatically with an increase in
Gem resistance (Fig. 3A). To determine whether Gem-
resistant cells exhibit an altered expression of ABC trans-
porters, western blotting analysis was performed. Among
the tested proteins, ABCD1 and MDR1 were highlyTable 2 Cross-resistance of gemcitabine-resistant sublines to v
Drug (mM) NTUB1 NG0.6
Ara-C 0.33  0.08 (1) 954.78  62.55 (2893.27)***
5-FU 8.58  1.17 (1) 5.85  0.43 (0.68)*
Cisplatin 2.64  0.2 (1) 3.73  0.37 (1.42)*
*p < 0.05, and ***p < 0.005.
Ara-C Z arabinofuranosyl cytidine; 5-FU Z 5-fluorouracil.augmented in NG sublines, while MRP1 and MRP9 were less
expressed and reduced (Fig. 3B).
Dysregulation of apoptosis and cell cycle-related
protein expression in Gem-resistant sublines
Molecular features of NG sublines were further investigated.
Cell-cycle regulator p21cip1 proteinwas significantly reduced
in NG sublines, whereas p27kip1, and cyclin-dependent ki-
nases 2 and 4 were increased (Fig. 4A). To identify the
cellular mechanisms responsible for the resistance observed
in NG sublines, the MAPK and AKT pathways were examined.
NTUB1 cells expressed undetectable JNK proteins [30]. NG
sublines exhibited lower p38 and ERK MAPK activities, and
minor changes in AKT and PTEN expressions (Fig. 4B and C).arious drugs.
NG0.8 NG1.0
410.78  5.23 (1244.79)*** 886.45  169.31 (2686.21)*
4.88  0.34 (0.57)* 4.66  0.53 (0.54)*
3.16  0.58 (1.20)* 3.75  0.91 (1.42)*
Figure 2. NG sublines display Gem resistance phenotypes. (A) NTUB1, NG0.6, NG0.8, and NG1.0 cells were seeded into IBIDI
culture insert containing wells. The insert was gently removed after overnight culturing, and the cells were observed and pho-
tographed 16 hours post insert removal (at 20 magnification). (B) The width of the wound space was measured and calculated by
the program Image J (http://rsb.info.nih.gov/ij/). Wound closure was determined as the difference between wound width at
0 hour and that at 16 hours, and expressed as a ratio to the 0-hour value. (C) ROS levels in NTUB1 and NG sublines were detected by
a DCFDA probe and analyzed by a FACScan flow cytometer, respectively. *p < 0.05. **p < 0.01. ***p < 0.005. DCFDA Z 2070-
dichlorofluorescein diacetate; Gem Z gemcitabine; ROS Z reactive oxygen species.
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The p38 MAPK inhibitor SB203580 and ERK MAPK inhibitor
PD98059 were employed to test whether MAPK activity was
critical for Gem sensitivity in NTUB1 cells. As shown in
Fig. 5A, SB203580 specifically promoted the survival of
NTUB1 cells in the presence of Gem, whereas PD98059
showed no effect. In addition, the ectopic expression ofFigure 3. NG sublines express Gem-resistant markers. (A) Tota
polymerase chain reaction to quantify the mRNA level of hENT1, d
[hENT1  dCK/RRM1  RRM2] was calculated accordingly and exp
duplicate wells were performed. (B) NTUB1 and NG sublines were h
antibodies. Densitometric quantifications of proteins are shown as
cassette protein; dCK Z deoxycytidine kinase; Gem Z gemcitab
MDR1 Z multidrug resistance protein 1; MRP Z multidrug resist
RRM2 Z ribonucleotide reductase subunit M2.p38 MAPK showed retarded migratory activity (Fig. 5B and
C) and enhanced Gem sensitivity (Fig. 5D) in NG1.0 cells.Discussion
Cancer cell-evoked Gem resistance has been addressed
[10]. In this study, we have established three serial Gem-l RNAs were isolated and analyzed by quantitative real-time
CK, RRM1, and RRM2 genes from indicated cells. The value of
ressed as a ratio to parent NTUB1 cells. Two experiments in
arvested and subjected to Western blot analysis with indicated
relative to a-tubulin. ABCD1Z adenosine triphosphate-binding
ine; hENT1 Z human equilibrative nucleoside transporter-1;
ance protein; RRM1 Z ribonucleotide reductase subunit M1;
Figure 4. Altered signaling pathways in NG sublines. (AeC) NTUB1, NG0.6, NG0.8, and NG1.0 cells were harvested and subjected
to Western blot analysis with indicated antibodies; a-tubulin was used as a loading control. Proteins were normalized to a-tubulin
by densitometric quantification. Phosphorylated proteins were further calculated to the total protein forms, accordingly.
CDK Z cyclin-dependent kinase; ERK Z extracellular signal-regulated kinase.
328 Y.-T. Kao et al.resistant sublines that can be studied in vitro to understand
better the cellular mechanisms involved in Gem resistance.
We provided evidence suggesting that acquired Gem resis-
tance in UC involves multiple mechanisms.
Chemoresistance is an important clinical problem incancer
management. Many molecular mechanisms have been pro-
posed; however, there is still no promising strategy for over-
coming this obstacle. Enzyme-mediated Gem transport and
nucleoside metabolizing enzymes play pivotal roles in devel-
oping drug resistance [11]. RRM1 expression was significantly
increased,whereas dCKwas reduced inNGsublines.RRM2and
hENT1 levels fluctuated in the cells. However, the levels of
[hENT1  dCK/RRM1  RRM2] correlated well with the Gem-
resistant phenotype (Fig. 3A). Furthermore, the concentra-
tive nucleoside transporter-1, 5-nucleotidase, thymidine ki-
nase 2, thymidylate synthase, and deoxycytidine deaminase
have also been suggested to play important roles in Gem
resistance in different systems [10,31,32].
The three established Gem-resistant sublines displayed
similar trends of cross-resistance to Ara-C but not to 5-FU
(Table 2). Ara-C and Gem are deoxycytidine-derived com-
pounds, whereas 5-FU is derived from uracil. Ara-C and Gem
share common metabolic and targeted pathways, and may
explain the cross-resistance in NG sublines. This observation
was supported by a study on pancreatic cancer [33]. Mild
resistance of these NG cells to cisplatin provided valuableinformation for their clinical use. Alteration of ABC trans-
porters was another main cause of drug resistance [15].
ABCD1 and MDR1 (ABCB1) were significantly elevated in the
Gem-resistant sublines (Fig. 3B). ABCD1 belongs to the ABC
subfamily D and has been suggested to be involved in the
transport of fatty acids. We have identified fatty acid syn-
thase as a Gem-induced gene in NTUB1 by a proteomic
approach [26]. Whether Gem resistance is associated with
the transport and metabolism of abnormal fatty acids merits
further investigation. In addition, MRP1 and MRP9 were low
and reduced in NG sublines as compared to parental cells.
MRP9 (ABCC12) has been demonstrated to be low in most
tissues [34]. A further detailed survey is needed.
Epithelial-to-mesenchymal transition is associated with
cancer metastasis, drug resistance, and cancer stem cell
phenotypes [35,36]. Enhanced migration activity was
observed in NG sublines, implying themalignant phenotype of
thesecells.Thecriticalmoleculeswill be investigated further.
Recent reports have demonstrated that the activation of
MAPK signaling pathways is often associated with chemo-
therapeutic drug sensitivity. Whether p38 MAPK activation
induced apoptosis or proliferation is still controversial. For
example, Habiro et al. [24] demonstrated that the p38
MAPK pathway was involved in Gem-induced cytotoxicity in
pancreatic cancer. Activation of p38 MAPK showed an
antiapoptotic effect in leukemia and lymphoma cell lines
Figure 5. Contribution of p38 MAPK to Gem sensitivity. (A) SB203580 (15 mM) or PD98059 (5 mM) was combined with various Gem
doses to analyze the cytotoxicity in NTUB1 cells using an MTT assay. The relative survival change was expressed as fold of Gem-
alone control. (B) NG1.0 cells were transfected with vector pcDNA3 or p38 expression plasmid. The expression of p38 protein
was performed by Western blot analysis. (C) The 24-hour post-transfected cells were seeded into a 24-well plate containing an IBIDI
culture insert. After overnight culture, the insert was gently removed and the migration of cells was observed and photographed 16
hours post insert at 200 magnification. (D) p38- and pcDNA3-transfected NG1.0 cells were seeded and MTT assay was performed.
The relative survival change is expressed as fold compared to pcDNA3 control. *p < 0.05. Gem Z gemcitabine; MAPK Z mitogen-
activated protein kinase; MTT Z modified 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide.
MAPK mediates gemcitabine sensitivity in UC 329[37]. In the current study, ERK and p38 MAPK signaling were
repressed in the Gem-resistant sublines (Fig. 4C). Inter-
estingly, inhibition of p38, but not of ERK MAPK, increased
the Gem resistance in NTUB1 cells significantly (Fig. 5A).
Forced expression of p38 MAPK impaired the migration ac-
tivity and sensitized Gem response in NG1.0 cells
(Fig. 5BeD). These results suggest that p38 MAPK can be a
potential pathway for targeting UC, and one should be
careful while applying a therapeutic strategy. Moreover,
the mechanisms of downregulation of p38 MAPK signaling
pathways in these NG cells warrant further study.
In summary, our data demonstrated that multiple
mechanisms are involved in developing Gem resistance, and
the p38 MAPK signaling pathway is a potential target for
developing novel UC therapy in the future.Acknowledgments
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